Vivos Therapeutics (VVOS) Preferred Stock Liabilities (2019)
Vivos Therapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $1.3 million for Q4 2019.
- Quarterly results put Preferred Stock Liabilities at $1.3 million for Q4 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was $1.3 million (changed N/A YoY), and the annual figure for FY2019 was $1.3 million, changed.
- Preferred Stock Liabilities for Q4 2019 was $1.3 million at Vivos Therapeutics.
- In the past five years, Preferred Stock Liabilities ranged from a high of $1.3 million in Q4 2019 to a low of $1.3 million in Q4 2019.